Most of these associations are in line with earlier IHC studies examining 10, 60, 82 and 314 breast tumors that had already suggested associations between p16 overexpression and adverse features of breast cancer such as high grade [7–10], nodal stage [10] and poor patient prognosis [9, 10]. Here, CDKN2A is linked to breast cancer.